Blue Jet Healthcare Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Blue Jet Healthcare Ltd is ₹ 421.55 as of 18 May 15:30 . The P/E Ratio of Blue Jet Healthcare Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Blue Jet Healthcare Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The Revenue of Blue Jet Healthcare Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Blue Jet Healthcare Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Blue Jet Healthcare Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Blue Jet Healthcare Ltd changed from 10.59 % to 6.82 % over 2 quarters. This represents a CAGR of -58.53% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

About Blue Jet Healthcare Ltd

Blue Jet Healthcare Limited was originally incorporated as Jet Chemicals Private Limited,' at Mumbai, dated December 7, 1968.
The Company name was changed to Blue Jet Healthcare Private Limited', and a fresh Certificate of Incorporation dated December 30, 2020, was issued by the Registrar of Companies, Mumbai.
Subsequently, the status got converted into a Limited Company and its name was changed to Blue Jet Healthcare Limited' on May 18, 2022. The Company is a global, science-led, pharmaceutical company evolved as strategic partner for Collaboration, Development & Manufacturing of Advance Pharmaceutical Intermediates and API. It operate into 3 product categories, contrast media intermediates, high- intensity sweeteners, and pharma intermediates and active pharmaceutical ingredients (APIs).

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Blue Jet Healthcare Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Blue Jet Healthcare Ltd or Sanofi India Ltd?

Market cap of Blue Jet Healthcare Ltd is 7,458 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Blue Jet Healthcare Ltd and Sanofi India Ltd?

The stock performance of Blue Jet Healthcare Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Blue Jet Healthcare Ltd and Sanofi India Ltd?

As of May 18, 2026, the Blue Jet Healthcare Ltd stock price is INR ₹429.95. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Blue Jet Healthcare Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Blue Jet Healthcare Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.